Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously
treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD)
after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with Platinum-doublet
Chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
BeyondSpring Pharmaceuticals Inc. Merck Sharp & Dohme LLC